T1 reduction rate with Gd-EOB-DTPA determines liver function on both 1.5 T and 3 T MRI.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 03 2022
18 03 2022
Historique:
received:
26
08
2021
accepted:
01
02
2022
entrez:
19
3
2022
pubmed:
20
3
2022
medline:
6
5
2022
Statut:
epublish
Résumé
Magnetic resonance T1 mapping before and after Gd-EOB-DTPA administration allows quantification of the T1 reduction rate as a non-invasive surrogate marker of liver function. A major limitation of T1 relaxation time measurement is its dependency on MRI field strengths. Since T1 reduction rate is calculated as the relative shortening of T1 relaxation time before and after contrast administration, we hypothesized that the T1 reduction rate is comparable between 1.5 and 3 T. We thus compared liver T1 relaxation times between 1.5 and 3 T in a total of 243 consecutive patients (124, 1.5 T and 119, 3 T) between 09/2018 and 07/2019. T1 reduction rates were compared between patients with no cirrhosis and patients with cirrhosis Child-Pugh A-C. There was no significant difference of T1 reduction rate between 1.5 and 3 T in any patient group (p-value 0.126-0.861). On both 1.5 T and 3 T, T1 reduction rate allowed to differentiate between patients with no cirrhosis and patients with liver cirrhosis Child A-C (p < 0.001). T1 reduction rate showed a good performance to predict liver cirrhosis Child A (AUC = 0.83, p < 0.001), Child B (AUC = 0.83, p < 0.001) and Child C (AUC = 0.92, p < 0.001). In conclusion, T1 reduction rate allows to determine liver function on Gd-EOB-DTPA MRI with comparable values on 1.5 T and 3 T.
Identifiants
pubmed: 35304554
doi: 10.1038/s41598-022-08659-2
pii: 10.1038/s41598-022-08659-2
pmc: PMC8933426
doi:
Substances chimiques
Contrast Media
0
gadolinium ethoxybenzyl DTPA
0
Gadolinium DTPA
K2I13DR72L
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4716Informations de copyright
© 2022. The Author(s).
Références
Eur Radiol. 2019 Jul;29(7):3584-3594
pubmed: 30903328
J Magn Reson Imaging. 2012 Sep;36(3):664-71
pubmed: 22532503
Abdom Radiol (NY). 2020 Oct;45(10):3129-3135
pubmed: 32185444
Sci Rep. 2017 Jan 27;7:41429
pubmed: 28128291
Invest Radiol. 2011 Apr;46(4):277-83
pubmed: 21343827
Clin Gastroenterol Hepatol. 2015 Mar;13(3):440-451.e6
pubmed: 25305349
Invest Radiol. 2005 Nov;40(11):715-24
pubmed: 16230904
World J Gastroenterol. 2018 May 14;24(18):2024-2035
pubmed: 29760545
Eur Radiol. 2020 Jan;30(1):370-382
pubmed: 31385048
Ann Hepatol. 2017 Jan-Feb 2017;16(1):48-56
pubmed: 28051792
Sci Rep. 2019 May 30;9(1):8106
pubmed: 31147588
Eur Radiol. 2012 Jun;22(6):1224-32
pubmed: 22302503
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
Biochem Biophys Res Commun. 1999 Apr 21;257(3):746-52
pubmed: 10208854
Lancet. 2015 Oct 17;386(10003):1576-87
pubmed: 26423181
Radiology. 2015 Feb;274(2):379-86
pubmed: 25289480
Oncotarget. 2018 Nov 20;9(91):36371-36378
pubmed: 30555635
Radiology. 2016 Nov;281(2):474-483
pubmed: 27195437
J Hepatol. 2001 Dec;35(6):765-73
pubmed: 11738104
J Magn Reson Imaging. 2017 Apr;45(4):1186-1194
pubmed: 27563840
J Hepatol. 2005;42 Suppl(1):S100-7
pubmed: 15777564
Magn Reson Imaging. 2015 Nov;33(9):1075-1082
pubmed: 26119422
Eur Radiol. 2019 Oct;29(10):5139-5147
pubmed: 30847587
Abdom Radiol (NY). 2019 Aug;44(8):2759-2768
pubmed: 31025071
Radiographics. 2019 Nov-Dec;39(7):1983-2002
pubmed: 31626569
Eur Radiol. 2016 Jun;26(6):1775-82
pubmed: 26373756
Eur Radiol. 2014 Apr;24(4):857-65
pubmed: 24356768
Eur J Radiol. 2013 Oct;82(10):1710-5
pubmed: 23806531
Eur J Radiol. 2011 Dec;80(3):e311-6
pubmed: 21315529
J Hepatol. 2012 Aug;57(2):421-9
pubmed: 22504332
Clin Exp Gastroenterol. 2018 Aug 23;11:301-307
pubmed: 30197529